Cargando…
The Efficacy and Safety of Pazopanib Plus Chemotherapy in Treating Recurrent or Persistent Ovarian Cancer: A Systematic Review and Meta-Analysis
Patients with recurrent or persistent ovarian cancer often have poor prognoses, and their optimal treatment regimen remains unclear. Inhibition of angiogenesis is a valuable strategy for treating ovarian cancer, and the drug pazopanib is a potent, multitarget tyrosine kinase inhibitor. However, trea...
Autores principales: | Zhang, Yaping, Fang, Hongming, Wang, Xiaoyan, Wang, Hui, Pan, Guoqiang, Chen, Jian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10205118/ https://www.ncbi.nlm.nih.gov/pubmed/36877187 http://dx.doi.org/10.1097/COC.0000000000000999 |
Ejemplares similares
-
Prognostic values of DNA mismatch repair genes in ovarian cancer patients treated with platinum-based chemotherapy
por: Zhao, Chuchu, et al.
Publicado: (2017) -
Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma: A Randomized Clinical Trial
por: Jones, Robin L., et al.
Publicado: (2022) -
Efficacy and Safety of the Surgery-First Approach Compared to the Chemotherapy-First Approach for Treating Low-Risk Gestational Trophoblastic Neoplasia: A Systematic Review and Meta-Analysis
por: Kamijo, Kyosuke, et al.
Publicado: (2023) -
An Indirect Comparison of the Efficacy and Safety of Dostarlimab and Doxorubicin for the Treatment of Advanced and Recurrent Endometrial Cancer
por: Mathews, Cara, et al.
Publicado: (2022) -
A phase 1/2a, dose-escalation, safety, pharmacokinetic, and preliminary efficacy study of intraperitoneal administration of BC-819 (H19-DTA) in subjects with recurrent ovarian/peritoneal cancer
por: Lavie, Ofer, et al.
Publicado: (2017)